title: Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life.
abstract: OBJECTIVE
  Lentinan (LNT), a purified beta-glucan, is a biological and immunological modifier and has been used as an anticancer drug in combination with 5-fluorouracil for gastric cancer in Japan. In this prospective randomized study, we evaluated the effects of LNT combination with regard to quality of life (QOL) and LNT binding ratio in monocytes.
  
  
  METHODS
  Twenty patients were evaluated for 12 weeks. One cycle was 3 weeks and S-1 (day1-14) and Paclitaxel (days1 and 8) were administered. LNT was used once a week (days 1, 8 and 15) and it was used for all 12 weeks in the LNT 12-wk group and only for the last 6 weeks in the LNT 6-wk group. QOL was evaluated weekly by QOL-ACD, and binding of LNT to monocytes was measured by flow cytometry.
  
  
  RESULTS
  There were individual variations in the binding ratio of LNT to monocytes from 0.16% to 11.95%. Toxicity with chemotherapy was not improved in the LNT 12-wk group, however, the total QOL score was significantly elevated in the LNT 12-wk group (p = 0.018) but not in the LNT 6-wk group.
  
  
  CONCLUSIONS
  LNT combination from the beginning of the chemotherapy may be an important factor for the improvement of patient QOL.
authors: Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. hkataoka@med.nagoya-cu.ac.jp
authors: Hiromi
authors: H
authors: Kataoka
authors: Takaya
authors: T
authors: Shimura
authors: Tsutomu
authors: T
authors: Mizoshita
authors: Eiji
authors: E
authors: Kubota
authors: Yoshinori
authors: Y
authors: Mori
authors: Takashi
authors: T
authors: Mizushima
authors: Tsuneya
authors: T
authors: Wada
authors: Naotaka
authors: N
authors: Ogasawara
authors: Satoshi
authors: S
authors: Tanida
authors: Makoto
authors: M
authors: Sasaki
authors: Shozo
authors: S
authors: Togawa
authors: Hitoshi
authors: H
authors: Sano
authors: Yoshikazu
authors: Y
authors: Hirata
authors: Masahiro
authors: M
authors: Ikai
authors: Hisato
authors: H
authors: Mochizuki
authors: Kyoji
authors: K
authors: Seno
authors: Sachie
authors: S
authors: Itoh
authors: Takashi
authors: T
authors: Kawai
authors: Takashi
authors: T
authors: Joh
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007912:Lentinan / Q000008:administration & dosage*; D008297:Male; D010094:Oxonic Acid / Q000008:administration & dosage*; D017239:Paclitaxel / Q000008:administration & dosage*; D011446:Prospective Studies; D011788:Quality of Life; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011795:Surveys and Questionnaires; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D007912:Lentinan; D010094:Oxonic Acid; D017239:Paclitaxel